Workflow
太平洋医药日报：IVIEW在研疗法IVIEW-1201获FDA，授予孤儿药资格
Tai Ping Yang·2025-04-10 10:25

Investment Rating - The overall industry investment rating is neutral, with specific sub-industry ratings as follows: Chemical Pharmaceuticals - no rating, Traditional Chinese Medicine - no rating, Biopharmaceutical II - neutral, Other Pharmaceuticals - neutral [3] Core Insights - As of April 9, 2025, the pharmaceutical sector experienced a slight increase of +0.37%, underperforming the CSI 300 index by 0.62 percentage points, ranking 28th among 31 sub-industries. The best-performing sub-industries included offline pharmacies (+2.72%), hospitals (+1.97%), and medical devices (+1.27%), while the worst performers were medical R&D outsourcing (-0.98%), blood products (-0.96%), and medical consumables (+0.19%) [5] - IVIEW announced that its IVIEW-1201 (1.0% Povidone-Iodine Ophthalmic Gel) has received orphan drug designation from the FDA for the treatment of fungal keratitis. This drug demonstrates a unique bactericidal mechanism and innovative delivery method, showing advantages in rapidly killing various pathogens without developing resistance, along with long-lasting release and high safety [6] Summary by Sections Market Performance - The pharmaceutical sector's performance on April 9, 2025, was +0.37%, lagging behind the CSI 300 index by 0.62 percentage points, with offline pharmacies, hospitals, and medical devices leading the gains [5] Industry News - IVIEW's IVIEW-1201 received orphan drug status from the FDA for treating fungal keratitis, showcasing a unique mechanism and delivery method [6] - Aohua Endoscopy reported a revenue of 750 million yuan for 2024, a year-on-year increase of 10.54%, but a net profit decline of 63.68% [6] - Wanfu Biology achieved a revenue of 3.065 billion yuan in 2024, up 10.85%, with a net profit increase of 15.18% [6] - Fuyuan Pharmaceutical's subsidiary received a drug registration certificate for Dapagliflozin tablets, enhancing its product line [7] - Haixiang Pharmaceutical announced a share buyback plan with a total amount of 150-300 million yuan [7]